Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Colorectal Neoplasms 36Colonic Neoplasms 10Rectal Neoplasms 8Neoplasm Metastasis 8Neoplasms 5Pancreatic Neoplasms 2Carcinoma, Neuroendocrine 2Adenocarcinoma 2Stomach Neoplasms 1Ras-mutated Metastatic Colorectal Cancer 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Metastatic Pancreatic Ductal Adenocarcinoma 1Metastatic Colorectal Adenocarcinoma 1Liver Metastasis Colon Cancer 1Gastrointestinal Neoplasms 1Exanthema 1Carcinoma, Basal Cell 1Carcinoma 1CRC 1Advanced Cancer 1

Interventions

Everolimus 9Cisplatin 8Temozolomide 6Nivolumab 5Etoposide 5Carboplatin 5Bevacizumab 5lutetium Lu 177 dotatate 4Capecitabine 4pembrolizumab 3Irinotecan 3sintilimab 2dostarlimab 2cabozantinib 2azaspirane 2avelumab 2atezolizumab 2Paclitaxel 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Ipilimumab 2Immunoglobulin G 2IFL protocol 2Fluorouracil 2Fluorodeoxyglucose F18 2Disulfides 2zimberelimab 1surufatinib 1selinexor 1pertuzumab 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Neuroendocrine × IFL protocol × Clear all
NCT02820857 2025-09-03

BEVANEC

Hospices Civils de Lyon

Phase 2 Completed
153 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT03168607 2017-06-01

Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma

Peking University

Phase 2 Unknown
45 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡